Human babesiosis caused by Babesia microti can be fatal in immunocompromised patients, and the currently used drugs are often ineffective. A recent study found that clofazimine clears B. microti Munich strain in immunocompromised mice. In the present study, we investigated the efficacies of clofazimine and 2-drug combinations involving clofazimine, atovaquone, and azithromycin against B. microti Peabody mjr strain in immunocompromised mice. Treatment with clofazimine alone, clofazimine plus azithromycin, and atovaquone plus azithromycin was ineffective and failed to eliminate the parasites completely, while a 44-day treatment with clofazimine plus atovaquone was highly effective and resulted in a radical cure.

中文翻译：

---

氯法齐明和 Atovaquone 的组合作为一种有效的治疗方案，用于根治免疫受损宿主中的巴贝虫感染

由小巴贝虫引起的人类巴贝虫病对免疫功能低下的患者可能是致命的，而目前使用的药物往往无效。最近的一项研究发现，氯法齐明可以清除免疫功能低下小鼠中的 B. microti Munich 菌株。在本研究中，我们研究了氯法齐明和包括氯法齐明、atovaquone 和阿奇霉素在内的 2 种药物组合对免疫受损小鼠中的 B. microti Peabody mjr 菌株的疗效。单独使用氯法齐明、氯法齐明加阿奇霉素和阿托伐醌加阿奇霉素治疗无效，未能完全消除寄生虫，而氯法齐明加阿托伐醌治疗 44 天非常有效，并导致根治。